Arbutus Biopharma Corporation Common Stock

Day range

$4.18 – $4.26

Open

$4.22

Prev close

$4.20

Volume

732.77K

Market cap

$832.04M

Shares out

198.11M

P/E

5.44

P/S

4.58

P/B

3.22

P/FCF

—

ROE

59.1%

ROA

55.8%

Debt/Equity

0.01

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionOct 22, 2026

  On October 22, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company's oral PD-L1 inhibitor.

• Tender offerAug 21, 2026

  On August 21, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its plans to launch a modified "Dutch auction" tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75.

• Deal terminationJul 16, 2026

  On July 15, 2026, Arbutus and Genevant entered into a termination agreement (the 'Termination Agreement') filed herewith as Exhibit 10.1 to terminate the RSV Agreement. Pursuant to the Termination Agreement, Genevant will pay Arbutus a termination fee of $1.0 million within ten business days of the date of the Termination Agreement, and all rights or obligations under the RSV Agreement are terminated.

• Annual meeting resultsMay 27, 2026

  On May 26, 2026, the Company held the Annual Meeting. At the Annual Meeting, the Company's shareholders voted and: (1) elected each of the Company's nominees for director; (2) approved the adoption of the 2026 Plan, (3) approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular; and (4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Regulatory decisionApr 15, 2026

  the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B. The FDA's Fast Track program is designed to facilitate the development and expedite the review of investigational therapies to treat serious conditions with unmet medical need.

Days to cover

3.5

Short interest

34.05M

Avg volume

9.65M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• 9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential
  neutralInvesting.com· Mar 5, 2026
• Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
  positiveBenzinga· Mar 4, 2026
• Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
  negativeThe Motley Fool· Feb 20, 2025
• Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
  Zacks Investment Research· Jun 13, 2024
• Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
  GlobeNewswire Inc.· Jun 6, 2024